Such action is not restricted to these scenarios or Pro(3)GIP and later studies published in 2015 using more specific GIPR antagonists, GIP(3-30)Cex-K(40)[PAL] and Pro(3)GIP(3-30)Cex-K(40)[PAL], similarly ameliorated insulin resistance and glucose intolerance in both DIO and db/db mice [169,1022]. The gene discussed is GIP; the disease is Insulin resistance.